Oesophageal Cancer Clinical Trials
Oesophageal Cancer
Learn More About Oesophageal Cancer
For general information on oesophageal cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| MTX-TROP2-302 | Oesophageal Cancer | MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors | Immunotherapy | TROP2 targeting. Low volume disease only. | Closed | Myeloid Therapeutics | NCT05969041 | Enquire Now |
| ADCE-T02-01 | Oesophageal Cancer | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| SSGJ-709-101 | Oesophageal Cancer | A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors | Immunotherapy | Anti-PD-1 and anti-LAG-3 bispecific antibody | Open - Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | NCT07016490 | Enquire Now |
| AMT-116-01 | Oesophageal Cancer | First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti-CD44v9 Antibody-Drug Conjugate | Open - Recruiting | Multitude Therapeutics Inc. | NCT05725291 | Enquire Now |
| AMT-253-01 | Oesophageal Cancer | First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | Anti-MUC18 | Open - Recruiting | Multitude Therapeutics (Australia) Pty Ltd | NCT05906862 | Enquire Now |
| HMBD-001-103 | Oesophageal Cancer | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanized IgG1 anti-HER3 monoclonal antibody + Combo treatment for squamous HER3 Mutation. | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| CP-IVX001 | Oesophageal Cancer | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487 | Enquire Now |
| ON-5001 | Oesophageal Cancer | A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas | Injectable Lesions | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Closed | OncoNano Medicine, Inc. | NCT06022029 | Enquire Now |